Silo Pharma Statistics
Total Valuation
Silo Pharma has a market cap or net worth of $3.20 million. The enterprise value is -$2.25 million.
Important Dates
The last earnings date was Friday, May 9, 2025, after market close.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Silo Pharma has 7.21 million shares outstanding. The number of shares has increased by 35.85% in one year.
| Current Share Class | 7.21M |
| Shares Outstanding | 7.21M |
| Shares Change (YoY) | +35.85% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | 2.82% |
| Owned by Institutions (%) | 3.45% |
| Float | 6.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.18 |
| Forward PS | n/a |
| PB Ratio | 0.50 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.73
| Current Ratio | 4.73 |
| Quick Ratio | 4.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -931.88 |
Financial Efficiency
Return on equity (ROE) is -99.38% and return on invested capital (ROIC) is -66.11%.
| Return on Equity (ROE) | -99.38% |
| Return on Assets (ROA) | -47.90% |
| Return on Invested Capital (ROIC) | -66.11% |
| Return on Capital Employed (ROCE) | -104.36% |
| Revenue Per Employee | $24,034 |
| Profits Per Employee | -$1.54M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.85% in the last 52 weeks. The beta is 1.71, so Silo Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | -76.85% |
| 50-Day Moving Average | 0.92 |
| 200-Day Moving Average | 1.16 |
| Relative Strength Index (RSI) | 31.80 |
| Average Volume (20 Days) | 638,965 |
Short Selling Information
The latest short interest is 67,438, so 0.94% of the outstanding shares have been sold short.
| Short Interest | 67,438 |
| Short Previous Month | 134,766 |
| Short % of Shares Out | 0.94% |
| Short % of Float | 1.03% |
| Short Ratio (days to cover) | 2.80 |
Income Statement
In the last 12 months, Silo Pharma had revenue of $72,102 and -$4.62 million in losses. Loss per share was -$1.13.
| Revenue | 72,102 |
| Gross Profit | 66,264 |
| Operating Income | -4.92M |
| Pretax Income | -3.60M |
| Net Income | -4.62M |
| EBITDA | n/a |
| EBIT | -4.92M |
| Loss Per Share | -$1.13 |
Full Income StatementBalance Sheet
The company has $5.45 million in cash and n/a in debt, giving a net cash position of $5.45 million or $0.76 per share.
| Cash & Cash Equivalents | 5.45M |
| Total Debt | n/a |
| Net Cash | 5.45M |
| Net Cash Per Share | $0.76 |
| Equity (Book Value) | 4.01M |
| Book Value Per Share | 0.89 |
| Working Capital | 4.42M |
Full Balance SheetCash Flow
| Operating Cash Flow | -4.64M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 91.90% |
| Operating Margin | -6,824.09% |
| Pretax Margin | -6,411.26% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |